Skip to content
  • My Accountmy account
  • Search
FLCCC | Front Line COVID-19 Critical Care Alliance
  • Treatment
    Protocols

    • Protocols

      Read about strategies to prevent and treat conditions like COVID-19, insulin resistance, RSV, long COVID, and more.

      Learn More
      Prevention

      Boost your immune system, clear your body of spike protein, and learn the benefits of intermittent fasting.

      • EAT WELL
      • I-PREVENT Vaccine Injury
      • See all Prevention Protocols
      Treatment

      At-home and hospital treatment plans for COVID, insulin resistance, sepsis, RSV and flu.

      • I-CARE Early At Home Treatment
      • I-CARE RSV and Flu Treatment
      • See all Treatment Protocols
      Recovery

      Approaches to managing symptoms from long COVID and long Vax.

      • I-RECOVER Post Vaccine Treatment
      • I-RECOVER Long Covid
      • See all Recovery Protocols
  • Medical
    Evidence
    • Reviews & Monographs

      In-depth academic pieces presenting original research, analysis, and evidence on complex conditions.

      Cancer Care
    • Studies

      A comprehensive listing of all research, studies, authors and sources cited in each FLCCC prevention and treatment protocol for COVID-19

      Learn More
    • Lectures

      Watch FLCCC doctors speak at international medical conferences, professional seminars and symposiums.

      Learn More
    • Senate Testimony

      Watch Dr. Pierre Kory testify before the U.S. Senate regarding FLCCC protocols to treat COVID-19.

      Learn More
  • COVID
    Resources

    • Wondering where to begin?

      Let us help you find what you’re looking for. We know COVID-19 can be overwhelming; click below to learn more about the resources available to you on this website.

      get started
      Patient Resources
      • Find a Provider
      • Find a Pharmacy
      • Tools & Guides
      • Testimonials
      • Hospital Guide
      Practitioner Resources
      • Efficacy of Ivermectin
      • Informed Consent
      • Nurses for FLCCC
      • Join the Alliance
      • Education on Demand
  • Education &
    Events

    • About the education portal

      FLCCC’s goal is to educate healthcare providers and empower patients with the tools and resources they need to take control of their own health.

      Events

      Our twice-yearly conferences bring top experts from a variety of fields together to learn, share, and network with each other.

      • Learn More
      Education on Demand

      Stream video lectures, download slide presentations, and get exclusive access to key facts, data, and references from FLCCC educational programs.

      • My Content
      • Explore Courses
  • News &
    Webinars
    • Latest Updates

      Stay up-to-date with the latest news from our fast-moving field.

      View
    • Blog

      Subscribe to our blog to read our weekly news capsule and be the first to receive the latest announcements from FLCCC.

      Read Now
    • Weekly Webinars

      Sign up for our webinars, every Wednesday at 7pm ET, offering the latest information on therapeutics and treatments and answering audience questions.

      Learn More
    • FLCCC in the News

      Read media coverage of FLCCC from around the world.

      View
  • About
    FLCCC

    • About the FLCCC

      Learn about the history of FLCCC, our mission and vision, and how you can get involved.

      learn more
      • Our Physicians
      • Our Partners
      • Advocacy
      • FAQ
      • Terms and Conditions
      • Impact Reports
      • Annual Reports
      • Support Us
      • Shop our Store
      • Connect with Us
  • Donate
  • Treatment Protocols
  • Find a Provider
  • Find a Pharmacy
  • Medical Evidence
    • Cancer Care
    • Studies
    • Lectures
    • Senate Testimony
  • COVID Resources
    • Get Started
    • Tools & Guides
    • Ivermectin
    • Hospital Guide
    • Nurses for FLCCC
    • Join The Alliance
  • Education & Events
    • Educational Conference
    • Education on Demand
    • My Content
  • News & Webinars
    • Latest Updates
    • FLCCC Blog
    • Weekly Webinars
    • FLCCC in the News
  • About The FLCCC
  • FAQ
  • Connect with Us
  • Donate
  • Cart
FLCCC | Front Line COVID-19 Critical Care Alliance
  • Treatment Protocols
  • Find a Provider
  • Find a Pharmacy
  • Medical Evidence
    • Cancer Care
    • Studies
    • Lectures
    • Senate Testimony
  • COVID Resources
    • Get Started
    • Tools & Guides
    • Ivermectin
    • Hospital Guide
    • Nurses for FLCCC
    • Join The Alliance
  • Education & Events
    • Educational Conference
    • Education on Demand
    • My Content
  • News & Webinars
    • Latest Updates
    • FLCCC Blog
    • Weekly Webinars
    • FLCCC in the News
  • About The FLCCC
  • FAQ
  • Connect with Us
  • Donate
  • Cart
Donate

References

Categories

I-CARE Early Covid (187) I-CARE Flu and RSV (36) I-PREVENT (153) I-RECOVER Long Covid (111) I-RECOVER Post-Vaccine (320) MATH+ (198)

Tags

ACE2 protein (10) acute respiratory distress syndrome (14) Alopecia (7) Anti-inflammatory (9) Antidepressants (9) Ascorbic Acid (12) autoantibodies (10) autophagy (24) Calcifediol (6) Cancer (9) Corticosteroids (9) COVID-19 (270) COVID-19 Vaccines (8) Curcumin (8) Cytokines (12) Depression (10) Famotidine (14) flavonoids (5) Glucocorticoids (7) Hydroxychloroquine (12) Hyperbaric Oxygen Therapy (9) Inflammation (14) ivermectin (47) long COVID (21) Mast Cells (8) Melatonin (20) Methylprednisolone (7) molnupiravir (5) N-Acetylcysteine (6) Non-Invasive Brain Stimulation (8) Omicron (7) Oxytocin (8) Pneumonia (8) quercetin (15) SARS-CoV-2 (72) SARS-CoV-2 mRNA Vaccines (7) Sepsis (18) spermidine (11) Spike Protein (10) Thiamine (7) Thrombosis (9) Tinnitus (12) Vitamin C (28) Vitamin D (10) Zinc (12)
  • Reference: Comparative effectiveness of famotidine in hospitalized COVID-19 patients

    Published On: April 11, 2021

    Famotidine has been posited as a potential treatment for coronavirus disease 2019 (COVID-19). We compared the incidence of COVID-19 outcomes (i.e., death and death or intensive services use) among hospitalized famotidine users vs proton pump inhibitors (PPIs) users, hydroxychloroquine users, or famotidine nonusers separately.

    Categories: MATH+

    Tags: COVID-19, Famotidine, Hydroxychloroquine

  • Reference: Comparative effectiveness of famotidine in hospitalized COVID-19 patients.

    Published On: April 4, 2021

    Authors: Shoaibi A, Fortin S, Weinstein R, Berlin JA PMID: 33982938 DOI: 10.14309/ajg.0000000000001153 Abstract Introduction: Famotidine has been posited as a potential treatment for coronavirus disease 2019 (COVID-19). We compared the incidence of COVID-19 outcomes (i.e., death and death or intensive services use) among hospitalized famotidine users vs proton pump inhibitors (PPIs) users, hydroxychloroquine users, [...]

    Categories: I-CARE Early Covid

    Tags: COVID-19, Famotidine

  • Reference: COVID-19: Famotidine, Histamine, Mast Cells, and mechanisms

    Published On: March 3, 2021

    SARS-CoV-2 infection is required for COVID-19, but many signs and symptoms of COVID-19 differ from common acute viral diseases. SARS-CoV-2 infection is necessary but not sufficient for development of clinical COVID-19 disease. Currently, there are no approved pre- or post-exposure prophylactic COVID-19 medical countermeasures. Clinical data suggest that famotidine may mitigate COVID-19 disease, but both mechanism of action and rationale for dose selection remain obscure.

    Categories: MATH+

    Tags: Famotidine, Histamine, histamine (H2) receptor, mast cell activating disorder, Mast Cells

  • Reference: Famotidine use is not associated with 30-day mortality: A coarsened exact match study in 7158 hospitalized COVID-19 patients from a large healthcare system

    Published On: February 16, 2021

    Previous reports have found that in-hospital famotidine use in coronavirus disease 2019 (COVID-19) patients was associated with reduced risk of death or intubation.1 , 2 In 1 of these studies the authors proposed that famotidine inhibits the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protease, 3-chymotrypsin-like protease, that is essential for breakdown of the immature SARS-CoV-2 protein particles that contribute to the inflammatory response seen in some COVID-19–infected individuals,1 which in turn can lead to acute respiratory distress syndrome, multiorgan dysfunction, physiologic deterioration, and death.3 In a global pandemic with a lack of US Food and Drug Administration–approved targeted therapeutic agents, identification and repurposing of well-established drugs with a proven track record of safety, affordability, and widespread availability are necessary.4 The purpose of this study was to evaluate the reported protective effect of famotidine on mortality in hospitalized COVID-19 patients.

    Categories: MATH+

    Tags: Famotidine

  • Reference: Famotidine use is not associated with 30-day mortality: A coarsened exact match study in 7158 hospitalized COVID-19 patients from a large healthcare system.

    Published On: October 12, 2020

    Authors: Yeramaneni S, Doshi P, Sands K, Cooper M, Kurbegov D, Fromell G PMID: 33058865 PMCID: PMC7550093 doi: 10.1053/j.gastro.2020.10.011 Abstract Previous reports have found that in-hospital famotidine use in coronavirus disease 2019 (COVID-19) patients was associated with reduced risk of death or intubation.1 , 2 In 1 of these studies the authors proposed that famotidine [...]

    Categories: I-CARE Early Covid

    Tags: COVID-19, Famotidine

  • Reference: Impact of famotidine use on clinical outcomes of hospitalized COVID-19 patients.

    Published On: October 11, 2020

    Authors: Mather JF, Seip RL, McKay RG PMID: 32852338 PMCID: PMC7473796 DOI: 10.14309/ajg.0000000000000832 Abstract Introduction: To compare outcomes in patients hospitalized with coronavirus (COVID-19) receiving famotidine therapy with those not receiving famotidine. Methods: Retrospective, propensity-matched observational study of consecutive COVID-19-positive patients between February 24, 2020, and May 13, 2020. Results: Of 878 patients in the [...]

    Categories: I-CARE Early Covid

    Tags: COVID-19, Famotidine

  • Reference: Impact of famotidine use on clinical outcomes of hospitalized COVID-19 patients

    Published On: October 10, 2020

    Introduction: To compare outcomes in patients hospitalized with coronavirus (COVID-19) receiving famotidine therapy with those not receiving famotidine. Methods: Retrospective, propensity-matched observational study of consecutive COVID-19-positive patients between February 24, 2020, and May 13, 2020.

    Categories: MATH+

    Tags: Famotidine

  • Reference: Efficacy of famotidine for COVID-19: A systematic review and meta-analysis.

    Published On: September 30, 2020

    Authors: Sethia R, Prasad M, Mahapatra SJ, Nischal N, Soneja M doi: https://doi.org/10.1101/2020.09.28.20203463 Abstract Background Coronavirus Disease 2019 (COVID-19) pandemic continues unabated in many parts of the world. In the absence of any definite antiviral therapy except some benefit of remdesivir, there is an ongoing search for effective therapy. Famotidine has been shown to reduce [...]

    Categories: I-CARE Early Covid

    Tags: COVID-19, Famotidine

  • Reference: Efficacy of famotidine for COVID-19: A systematic review and meta-analysis

    Published On: September 20, 2020

    Coronavirus Disease 2019 (COVID-19) pandemic continues unabated in many parts of the world. In the absence of any definite antiviral therapy except some benefit of remdesivir, there is an ongoing search for effective therapy. Famotidine has been shown to reduce mortality in hospitalized patients in a few studies. We conducted a systematic review on the use of famotidine in COVID-19.

    Categories: MATH+

    Tags: Famotidine

  • Reference: Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalized patients: a case series

    Published On: September 5, 2020

    Conclusions: The results of this case series suggest that high-dose oral famotidine is well tolerated and associated with improved patient-reported outcomes in non-hospitalised patients with COVID-19.

    Categories: MATH+

    Tags: COVID-19, Famotidine, PROMs, SARS-CoV-2

12Next
FLCCC Logo with white letters
Support Us

We are a 100% donor-supported 501(c)(3) non-profit organization. Our work would not be possible without you! Help us expand our reach and share life-saving research.

Give Now
shop
Contact Us
Mailing Address

FLCCC Alliance
2001 L St. NW Suite 500
Washington, DC 20036

Media

[email protected]

Clinical Support

[email protected]

General

[email protected]